Related Experiment Video
Updated: Oct 19, 2025
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.7K
Targeting HER2 heterogeneity in breast cancer
Erika Hamilton1, Mythili Shastry2, S Michelle Shiller3
1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States.
Cancer Treatment Reviews
|September 17, 2021
Summary
New breast cancer treatments targeting Human Epidermal Growth Factor Receptor 2 (HER2) are emerging for HER2-low and heterogeneous tumors. Refining HER2 expression classification is crucial for optimizing patient care across the spectrum.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapies have transformed HER2-positive breast cancer treatment.
- Increasing recognition of low or heterogeneous HER2 expression impacts treatment efficacy.
- Novel antibody drug conjugates enable targeting of HER2-low expressing tumors.
Purpose of the Study:
- To highlight the clinical significance of HER2 heterogeneity in breast cancer.
- To emphasize the need for refined nomenclature for HER2 expression.
- To underscore the necessity of developing new diagnostic and therapeutic strategies for HER2-low and heterogeneous breast cancers.
Main Methods:
- Review of current understanding of HER2 expression in breast cancer.
- Analysis of the impact of HER2 heterogeneity on treatment outcomes.
- Discussion of diagnostic methods for HER2 heterogeneity, including IHC and gene expression profiling.
Main Results:
- HER2 heterogeneity is increasingly recognized and affects response to HER2-targeted therapies.
- HER2 heterogeneity correlates with shorter disease-free survival (DFS) and overall survival (OS).
- Targeting HER2-low tumors with advanced therapies like antibody drug conjugates is becoming feasible.
Conclusions:
- Refined classification of HER2 expression is essential for personalized breast cancer treatment.
- Clinical validation of techniques to detect HER2 heterogeneity is required.
- Development of novel therapeutic agents for non-uniformly expressed HER2 tumors is needed.
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:38Mitogens and the Cell Cycle
7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K